BCL2 and cancer: The dysregulation of the MAPK–ERK signalling pathway is involved in the malignant transformation of several cancers,53 including leukaemia with ERK‐mediated increase in anti‐apoptotic proteins, BCL‐2, and BCL‐XL is contributing to disease progression.54